## WHAT IS CLAIMED IS:

1. A water soluble hydrid phthalocyanine derivative.

2. A derivative of claim 1 wherein the derivative is silicon[di(1,6-diphenyl-2,3 naphthalocyanine)]diphthalocyanine bis [poly(ethylene glycol) methyl ether].

3. A derivative of claim 1 wherein the derivative is silicon[di(1,6-diphenyl-2,3-naphthalocyanine)]diphthalocyanine bis[poly(ethylene glycol)].

- 4. A derivative of claim 1 wherein the derivative is silicon [di(1,6-diphenyl-2,3 naphthalocyanine)] diphthalocyanine [poly(ethylene glycol)][poly(ethylene glycol)acetylthiopropionate].
- 5. A derivative of claim 1 wherein the derivative is silicon[di(1,6-diphenyl 2,3-naphthalocyanine)]di(2,3-dicarboxyphthalocyanine)dihydroxide.
- 6. A derivative of claim 1 wherein the derivative is silicon[di(1,6-diphenyl 2,3-naphthalocyanine)]di(2,3-dicarboxyphthalocyanine) bis[poly(ethylene glycol)methylether].
- 7. A derivative of claim 1 wherein the derivative is sulfo silicon di[(1,6-diphenyl-2,3-naphthalocyanine] diphthalocyanine dihydroxide.

10

5

I have been some one construction of the second state of the second state of the second state of the second second

20

25

30

9. A derivative of claim 1 wherein the derivative is sulfo silicon di[(1,6-diphenyl-2,3-naphthalocyanine]diphthalocyanine[-2-butyrothiolactone)amidomethoxide]hydroxide.

- 10. A derivative of claim 1 wherein the derivative is sulfo silicon di[(1,6-diphenyl-2,3-naphthalocyanine]diphthalocyanine[N-(cysteine)amidomethoxide]hydroxide.
- 11. A derivative of claim 1 wherein the derivative is silicon tetra-tert-butylphthalocyanine bis [(4-aminobutyl) dimethylsilyloxide].
- 12. A derivative of claim 1 wherein the derivative is sulfo[2<sup>1</sup>,2<sup>6</sup>,12<sup>1</sup>,12<sup>6</sup>-tetraphenyldinaphtho[b,1]-7,17-dibenzo[g,q]-5,10, 15,20-tetrazoporphyrinato]silicon dihydroxide.
- 13. A derivative of claim 1 wherein the derivative is  $sulfo[2^1,2^6,12^1,12^6-tetraphenyldinaphtho[b,1]-7,17-dibenzo[g,q]-5,10, 15,20-tetraazoporphyrinato] silicon bis (4-Aminobutyldimethylsilyloxide).$

10

5

25

5

15. A derivative of claim 1 wherein the derivative is sulfo[2<sup>1</sup>,2<sup>6</sup>,12<sup>1</sup>,12<sup>6</sup>-tetraphenyldinaphtho[b,1]-7,17-dibenzo[g,q]-5,10, 15,20-tetraazoporphyrinato]silicon bis-[(10-carbomethoxydecyl) dimethyl silyloxide].

10

16. A derivative of claim 1 wherein the derivative is sulfo[2¹,26,12¹,126-tetraphenyldinaphtho[b,1]-7,17-dibenzo[g,q]-5,10, 15,20-tetraazoporphyrinato]silicon bis (7-oct-1-enyldimethylsilyloxide).

17. A derivative of claim 1 wherein the derivative is sulfo silicon naphthalocyanine bis (4-aminobutyldimethyl silyloxide).

20 X

18. A derivative of claim 1 wherein the derivative is sulfo silicon naphthalocyanine bis [10-(carbomethoxy)decyl dimethylsilyloxide].

\_ .

19. A derivative of claim 1 wherein the derivative is sulfo silicon naphthalocyanine bis(3-aminopropyldiisopropylsilyloxide).

25

30

20. A derivative of claim 1 wherein the derivative is sulfo[2<sup>1</sup>,2<sup>6</sup>,12<sup>1</sup>,12<sup>6</sup>-tetraphenyldinaphtho[b,1]-7,17-dibenzo[g,q]-5,10, 15,20-tetraazoporphyrinato]silicon bis[N-succinamido)aminobutyldimethyl silyloxide.

21. A derivative of claim 1 wherein the derivative is sulfo[2¹,26,12¹,126-tetraphenyldinaphtho[b,1]-7,17-dibenzo[g,q]-5,10, 15,20-tetrazoporphyrinato]silicon bis[4[(acetylthiopropionamido) butyl] dimethylsilyloxide].

10

5

avi, and, and, and and mar mar and.

J. H. Mall, J. J. May, Juga, Juga Hag, May, ..., I. H. Mall, Juga Hag, May, and then are and a second at the same are same and a second at the same are same.

22. A derivative of claim 1 wherein the derivative is sulfo[2¹,26,12¹,126-tetraphenyldinaphtho[b,1]-7,17-dibenzo[g,q]-5,10, 15,20-tetrazoporphyrinato]silicon bis[4[(thiopropionamido)butyl] dimethylsilyloxide].

- 23. A conjugate comprising a sulfonated hybrid phthalocyanine derivative and a substituent.
- 24. A conjugate of claim 23 wherein the substituent is an antibody.
- 25. A conjugate of claim 24 wherein the antibody specifically binds to human chorionic gonadotropin.
- 26. A conjugate of claim 23 wherein the substituent is a ligand analogue.
- 27. The conjugate of claim 26 wherein the ligand analogue is morphine.

10

5

J. H. Jing, Jing, pard they from "

- amount of at least one target ligand capable of competing with a ligand analogue conjugate for binding sites available on a ligand receptor, said ligand analogue conjugate comprising at least one ligand analogue coupled to a signal development element, said signal development element comprising a water soluble phthalocyanine derivative, in a fluid sample suspected of containing said target ligand comprising the steps of:
- a. contacting said fluid sample with said ligand analogue conjugate and said ligand receptor to form a homogeneous reaction mixture;
- b. detecting bound or unbound ligand analogue conjugates in said reaction mixture using said water soluble phthalocyanine derivative; and,
- c. relating the detectable signal to the presence or amount of said target ligand in said fluid sample.
- 29. A method of determining the presence or amount of at least one ligand in a fluid sample suspected of containing said target ligand comprising the steps of:
- a. contacting said fluid sample with a receptor said receptor coupled to a signal development element comprising a water soluble phthalocyanine derivative, so that said receptor specifically binds said target ligand to form a homogeneous reaction mixture;
- b. detecting bound receptor in said reaction mixture using said water soluble phthalocyanine derivative; and,
- or amount of said target ligand in said fluid sample.

10

5

15

도 신 20 차

25

30